A Study to Evaluate the Efficacy of Juglandis Semen Complex Extract on Knee Articulation Health

A Pilot Study to Evaluate the Efficacy of Juglandis Semen Complex Extract on Knee Articulation Health: Randomized, Double-blind Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0003552

Enrollment

Registered

2019-02-25

Start date

2019-04-02

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Test supplement1 : Juglandis Semen complex extract (Juglandis Semen, Eucommiae Cortex, Acanthopanacis Cortex, Zingiberis Rhizoma 1000 mg/day) Test supplement2 : Juglandis Semen c

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) 40-75 year old male and female with knee pain for 6 months or more (2) A Kellgren-Lawrence grading scale of 1 grade or 2 grade on both knee X-ray examinations (3) If subject is taking arthritic medications, subject has not changed his/her medication within the past a month (4) Subject who agrees to participate in the study and signs the informed consent form

Exclusion criteria

Exclusion criteria: (1) A person who is arthritis due to a specific factor other than degenerative (2) Those who have a history of fractures of the lower limb within the last 3 months (3) A patient who received intra-articular injection with hyaluronic acid or steroids within 3 months of the study (4) Continuous intake of steroids, non-steroidal anti-inflammatory drugs and health functional foods (glucosamine, MSM, green lipped mussel extract oil, etc.) that may affect joint health within the past month (5) Those who complain of severe gastrointestinal symptoms such as heartburn and indigestion (6) Alcohol abuser (7) Those who have clinically significant cardiovascular, immune, infectious, and neoplastic diseases other than arthralgia (8) Persons suspected of having liver disease, kidney disease, or blood disease (9) Persons who have experienced habitual administration of psychotropic drugs and narcotic analgesics that may affect pain sensation (10) Those who are pregnant or breastfeeding (11) Any other researcher deemed inappropriate for this test (12) Persons with food allergies to nuts, etc. (13) Those who participated in other clinical trials within 30 days

Design outcomes

Primary

Measure	Time frame
K-WOMAC(Korean Western ontario and McMaster Universities Questionnaire)	—

Secondary

Measure	Time frame
VAS(Visual Analog Scale);EQ-5D(EuroQol-5D);PGIC(Patient Global Impression of Change);Inflammation markers;Adverse event	—

Countries

Korea, Republic of

Contacts

Public ContactHae-jin Kong

Cheonan Korean Medicine Hospital of Daejeon University

haejin9212@gmail.com+82-41-521-7549

Outcome results